GSK forms hypertension alliance

pharmafile | June 29, 2005 | News story | Sales and Marketing  

GlaxoSmithKline has formed a strategic alliance with an emerging pharma company to develop and commercialise novel compounds to treat hypertension and other cardiovascular disorders.

Vitae Pharmaceuticals has developed multiple, novel chemical series of renin inhibitors and under the alliance the companies will pool their respective renin programmes to identify and select compounds for clinical development.

GSK will then lead and fund the development and commercialisation of renin inhibitors, which both companies hope to see emerge as a new class of cardiovascular drugs.

The Fort Washington-based company will receive an upfront payment from GSK, research funding and further milestone payments as part of their agreement.

Vitae said aggregate payments from GSK during the pre-commercial activities for its lead product would be $175 million. The company will also receive royalties on the sale of all products upon commercialisation and retains the right to co-promote any product in the US resulting from this alliance.

Related Content

No items found

Latest content